{"id":11319,"date":"2023-11-21T22:33:00","date_gmt":"2023-11-21T14:33:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11319"},"modified":"2024-11-04T22:51:17","modified_gmt":"2024-11-04T14:51:17","slug":"belgium-bans-ozempic-for-weight-loss-as-global-shortage-persists","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11319","title":{"rendered":"Belgium Bans Ozempic for Weight Loss as Global Shortage Persists"},"content":{"rendered":"\n

Belgium has issued a royal decree prohibiting the use of Novo Nordisk’s (NYSE: NVO<\/a>) diabetes drug Ozempic (semaglutide) for weight-loss treatment, following a similar move by the UK in July, according to a Reuters report. Despite previous requests in October 2022 for doctors to cease off-label prescriptions for obesity, the measure had minimal impact. Germany is considering banning the export of Ozempic to ensure domestic supply.<\/p>\n\n\n\n

Ozempic is marketed under three tradenames: Wegovy for weight management, Ozempic for type 2 diabetes, and Rybelsus for blood sugar control, all approved by the US FDA and the EU. Off-label use for weight loss has led to a global shortage of semaglutide, exacerbated by celebrity endorsements. Novo Nordisk CEO Lars Fruergaard J\u00f8rgensen anticipates continued supply-demand imbalance in the short to medium term.<\/p>\n\n\n\n

Supply Disruptions and Market Impacts<\/strong><\/p>\n\n\n\n

Novo Nordisk updated its official website on November 10th, citing “continuous supply disruptions” and announcing restrictions on low-dose wholesalers to retail pharmacies. In the US, compound drugs of Ozempic and Wegovy appeared due to tight supply, leading to adverse reaction reports to the FDA. In China, Ozempic was first approved in April 2021 and is now used off-label for weight loss, with sales volume increasing significantly due to loose regulation. The drug is covered by the National Reimbursement Drug List (NRDL) for diabetes treatment, not weight loss, indicating high demand and low supply.<\/p>\n\n\n\n

Wegovy’s sales reached USD 3.156 billion in Q1-Q3 2023, a 481% year-on-year increase. In China, Huadong Medicine\u2019s Liluping (liraglutide) and Benemae Pharma\u2019s benaglutide are available for weight loss, competing with Ozempic in a market driven by diabetes and weight loss demands.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Belgium has issued a royal decree prohibiting the use of Novo Nordisk’s (NYSE: NVO) diabetes…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[148,860,86],"class_list":["post-11319","post","type-post","status-publish","format-standard","hentry","category-company","tag-novo-nordisk","tag-nyse-nvo","tag-obesity"],"yoast_head":"\nBelgium Bans Ozempic for Weight Loss as Global Shortage Persists - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Belgium has issued a royal decree prohibiting the use of Novo Nordisk's (NYSE: NVO) diabetes drug Ozempic (semaglutide) for weight-loss treatment, following a similar move by the UK in July, according to a Reuters report. Despite previous requests in October 2022 for doctors to cease off-label prescriptions for obesity, the measure had minimal impact. Germany is considering banning the export of Ozempic to ensure domestic supply.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11319\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Belgium Bans Ozempic for Weight Loss as Global Shortage Persists\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11319\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-21T14:33:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-04T14:51:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11319#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11319\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Belgium Bans Ozempic for Weight Loss as Global Shortage Persists\",\"datePublished\":\"2023-11-21T14:33:00+00:00\",\"dateModified\":\"2024-11-04T14:51:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11319\"},\"wordCount\":281,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11319#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11319\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11319\",\"name\":\"Belgium Bans Ozempic for Weight Loss as Global Shortage Persists - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-21T14:33:00+00:00\",\"dateModified\":\"2024-11-04T14:51:17+00:00\",\"description\":\"Belgium has issued a royal decree prohibiting the use of Novo Nordisk's (NYSE: NVO) diabetes drug Ozempic (semaglutide) for weight-loss treatment, following a similar move by the UK in July, according to a Reuters report. Despite previous requests in October 2022 for doctors to cease off-label prescriptions for obesity, the measure had minimal impact. Germany is considering banning the export of Ozempic to ensure domestic supply.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11319#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11319\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11319#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Belgium Bans Ozempic for Weight Loss as Global Shortage Persists\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Belgium Bans Ozempic for Weight Loss as Global Shortage Persists - Insight, China's Pharmaceutical Industry","description":"Belgium has issued a royal decree prohibiting the use of Novo Nordisk's (NYSE: NVO) diabetes drug Ozempic (semaglutide) for weight-loss treatment, following a similar move by the UK in July, according to a Reuters report. Despite previous requests in October 2022 for doctors to cease off-label prescriptions for obesity, the measure had minimal impact. Germany is considering banning the export of Ozempic to ensure domestic supply.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11319","og_locale":"en_US","og_type":"article","og_title":"Belgium Bans Ozempic for Weight Loss as Global Shortage Persists","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11319","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-21T14:33:00+00:00","article_modified_time":"2024-11-04T14:51:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11319#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11319"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Belgium Bans Ozempic for Weight Loss as Global Shortage Persists","datePublished":"2023-11-21T14:33:00+00:00","dateModified":"2024-11-04T14:51:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11319"},"wordCount":281,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Novo Nordisk","NYSE: NVO","Obesity"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11319#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11319","url":"https:\/\/flcube.com\/?p=11319","name":"Belgium Bans Ozempic for Weight Loss as Global Shortage Persists - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-21T14:33:00+00:00","dateModified":"2024-11-04T14:51:17+00:00","description":"Belgium has issued a royal decree prohibiting the use of Novo Nordisk's (NYSE: NVO) diabetes drug Ozempic (semaglutide) for weight-loss treatment, following a similar move by the UK in July, according to a Reuters report. Despite previous requests in October 2022 for doctors to cease off-label prescriptions for obesity, the measure had minimal impact. Germany is considering banning the export of Ozempic to ensure domestic supply.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11319#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11319"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11319#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Belgium Bans Ozempic for Weight Loss as Global Shortage Persists"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11319"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11319\/revisions"}],"predecessor-version":[{"id":11320,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11319\/revisions\/11320"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}